scholarly journals Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

Diabetologia ◽  
2010 ◽  
Vol 53 (4) ◽  
pp. 614-623 ◽  
Author(s):  
B. Keymeulen ◽  
M. Walter ◽  
C. Mathieu ◽  
L. Kaufman ◽  
F. Gorus ◽  
...  
Diabetes Care ◽  
2014 ◽  
Vol 38 (1) ◽  
pp. 178-178 ◽  
Author(s):  
Itamar Raz ◽  
Anette G. Ziegler ◽  
Thomas Linn ◽  
Guntram Schernthaner ◽  
Francois Bonnici ◽  
...  

Life ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. 213
Author(s):  
Taylor Marie Richards ◽  
Aixia Sun ◽  
Hasaan Hayat ◽  
Neil Robertson ◽  
Zhaoda Zhang ◽  
...  

Islet transplantation has great potential as a cure for type 1 diabetes. At present; the lack of a clinically validated non-invasive imaging method to track islet grafts limits the success of this treatment. Some major clinical imaging modalities and various molecular probes, which have been studied for non-invasive monitoring of transplanted islets, could potentially fulfill the goal of understanding pathophysiology of the functional status and viability of the islet grafts. In this current review, we summarize the recent clinical studies of a variety of imaging modalities and molecular probes for non-invasive imaging of transplanted beta cell mass. This review also includes discussions on in vivo detection of endogenous beta cell mass using clinical imaging modalities and various molecular probes, which will be useful for longitudinally detecting the status of islet transplantation in Type 1 diabetic patients. For the conclusion and perspectives, we highlight the applications of multimodality and novel imaging methods in islet transplantation.


2018 ◽  
Author(s):  
Peter Seiron ◽  
Anna Wiberg ◽  
Lars Krogvold ◽  
Frode Lars Jahnsen ◽  
Knut Dahl-Jørgensen ◽  
...  

AbstractInsulin deficiency in type 1 diabetes (T1D) is generally considered a consequence of specific beta-cell loss. Since healthy pancreatic islets consist of ~65% beta cells, this would lead to reduced islet size if the beta cells are not replaced by other cells or tissue. The number of islets per pancreas volume (islet density) would not be affected.In this study, we compared the islet density, size, and size distribution in subjects with recent-onset or long-standing T1D, with that in matched non-diabetic subjects. Results show that subjects with T1D, regardless of disease duration, had a dramatically reduced islet number per mm2, while the islet size was similar in all groups. Insulin-negative islets in T1D subjects were dominated by glucagon-positive cells that frequently had lost the alpha-cell transcription factor ARX while instead expressing PDX1, normally expressed in beta cells.Based on our findings, we propose that failure during childhood to establish a sufficient islet number to reach the beta-cell mass needed to cope with episodes of increased insulin demand contributes to T1D susceptibility. Exhaustion induced by relative lack of beta cells could then potentially drive beta-cell dedifferentiation to alpha-cells, explaining the preserved islet size observed in T1D compared to controls.


2021 ◽  
Vol 249 (2) ◽  
pp. T1-T11
Author(s):  
Pieter-Jan Martens ◽  
Conny Gysemans ◽  
Chantal Mathieu

Type 1 diabetes is one of the most common chronic diseases in children and adolescents, but remains unpreventable and incurable. The discovery of insulin, already 100 years ago, embodied a lifesaver for people with type 1 diabetes as it allowed the replacement of all functions of the beta cell. Nevertheless, despite all technological advances, the majority of type 1 diabetic patients fail to reach the recommended target HbA1c levels. The disease-associated complications remain the true burden of affected individuals and necessitate the search for disease prevention and reversal. The recognition that type 1 diabetes is a heterogeneous disease with an etiology in which both the innate and adaptive immune system as well as the insulin-producing beta cells intimately interact, has fostered the idea that treatment to specific molecular or cellular characteristics of the patient groups will be needed. Moreover, robust and reliable biomarkers to detect type 1 diabetes in the early (pre-symptomatic) phases are wanted to preserve functional beta cell mass. The pitfalls of past therapeutics along with the perspectives of current therapies can open up the path for future research.


1994 ◽  
Vol 38 (3) ◽  
pp. 249-258 ◽  
Author(s):  
K. Spiess ◽  
G. Sachs ◽  
G. Moser ◽  
P. Pietschmann ◽  
G. Schernthaner ◽  
...  

2000 ◽  
Vol 54 (4) ◽  
pp. 181-185 ◽  
Author(s):  
J.R. Bilbao ◽  
I. Rica ◽  
J.A. Vázquez ◽  
M.A. Busturia ◽  
L. Castaño

Diabetes Care ◽  
2014 ◽  
Vol 37 (5) ◽  
pp. 1392-1400 ◽  
Author(s):  
Itamar Raz ◽  
Anette G. Ziegler ◽  
Thomas Linn ◽  
Guntram Schernthaner ◽  
Francois Bonnici ◽  
...  

Author(s):  
Johnny Ludvigsson ◽  
Indusmita Routray ◽  
Tore Vigård ◽  
Ragnar Hanås ◽  
Björn Rathsman ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document